This is a working overview of analytical methods, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-16 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
=== Contestants === 1st - Manny Martinez, Bakery Owner from San Antonio, Texas 2/3/4th - Aaron Davis, Pastry Lead from Surprise, Arizona. 2/3/4th - Joel Gonzalez, Executive Pastry Chef from Scottsdale, Arizona 2/3/4th - Hollie Rivera, Assistant Pastry Chef from Winnipeg, Manitoba 5th - Lillian Chng, Home Bakery Owner from San Diego, California 6th - Thierry Aujard, Executive Pastry Chef from Norristown, Pennsylvania 7th - Megan Aucone, Pastry Chef and Cake Artist from Sayreville, New Jersey 8th - JL Hinojosa, Pastry Chef de Partie from Austin, Texas 9th - Carly Robertson, Bakery Owner from Lehi, Utah 10th - Samantha Santiago Torres, Executive Pastry Chef from Chicago, Illinois
=== Diminished sensitivity, associated with diabetes risk === Although many factors influence insulin secretion, the most important control is the amount of glucose moving from the blood into the beta cells of the pancreas. In healthy people, even small rises in blood glucose result in increased insulin secretion. As long as the pancreatic beta cells are able to sense the glucose level and produce insulin, the amount of insulin secreted is usually the amount required to maintain a fasting blood glucose between 70 and 100 mg/dL (3.9–5.6 mmol/L) and a non-fasting glucose level below 140 mg/dL (<7.8 mmol/L). When liver cells and other cells that remove glucose from the blood become less sensitive (more resistant) to the insulin, the pancreas increases secretion and the level of insulin in the blood rises. This increased secretion can compensate for reduced sensitivity for many years, with maintenance of normal glucose levels. However, if insulin resistance worsens or insulin secretion ability declines, the glucose levels will begin to rise. Persistent elevation of glucose levels is termed diabetes mellitus. Typical fasting insulin levels found in this type of hyperinsulinism are above 20 μU/mL. When resistance is severe, levels can exceed 100 μU/mL. In addition to being a risk factor for type 2 diabetes, hyperinsulinism due to insulin resistance may increase blood pressure and contribute to hypertension by direct action on vascular endothelial cells (the cells lining blood vessels).
In 1990, following cumulative $8.5 million donations by Bronx businessman Jack Resnick, Einstein's campus was designated as the Jack and Pearl Resnick Campus. Six years later, Einstein built a 10-story research complex, the Samuel H. and Rachel Golding Building. In 2002, the college opened the three-story Gruss Magnetic Resonance Research Center. Equipped with magnetic resonance equipment beyond conventional MRI, the center was one of six such facilities in the world upon opening. In 2008, Einstein opened a $225 million research complex, the Price Center. This expansion doubled the size of Einstein's campus to nearly 40 acres. Also that year, the college replaced its old logo—a "staid" portrait of Albert Einstein—with a stylized symbol that represents the helical structure of DNA, a notable spiral staircase on campus, and 'E' for Einstein. In 2024, Ruth Gottesman—a long-time professor at the medical school and head of the board of trustees—donated $1 billion to the school to make tuition free for all students in perpetuity. The contribution also stipulated that the college never change its name. The donation was one of the largest to any educational institution, and, according to The New York Times, likely the largest donation to any medical school.
Sources: en.wikipedia.org
Collins, who has suffered with urinary incontinence herself, said of the collaboration that she wanted to "help break down the stigma around the subject for women", describing it as "a taboo subject" and said that "it's really sad to know that women are stopping doing their activities because of leaks." Collins said she was "so surprised to find out how many women, just like [her], [were] also experiencing bladder leaks" adding that she had previously "held back on doing things [she enjoyed], like trampolining, riding a bike or working out, and dancing the night away with friends, because [she] was worried about bladder leaks" and that "since learning that pelvic floor exercises can help to manage them, and using pads for those moments when [she needed] more protection, [she] no longer [had] to hold back." Collins continued to collaborate with the brand over the following year to "get women talking and empower those experiencing bladder leaks to live life without compromise" and subsequently discussed her own experience on This Morning. In July 2023, she collaborated with the internet service provider Plusnet, for which she assumed the role of an agony aunt and answered queries from the public in an online video segment titled "Gemma's Dilemmas". Collins said of her role: "From technology mishaps to fashion disasters, I know what it's like to deal with daily frustrations and so this is why I am launching my new campaign, Gemma's Dilemmas, to give my advice to the nation and solve their problems – one step at a time.
Smear layer will fill the orifices of the dentinal tubules, hence forming smear plugs. These smear plugs decrease dentin permeability by 90% and the smear plug alone can prevent adhesive resin penetration into dentinal tubules. The thickness of smear layer can range from 0.5-2 μmeter and for the smear plug, 1 to 10 μmeter. Smear layer poses some threat for optimal bonding to occur. That is why it needs to be removed. For example, smear layer needs to be removed prior to bonding by etch-and-rinse (total etch) adhesives. This will lead to thicker hybrid layer and long, denser resin tags which results in better bond strength.
== Functions == Dense regular connective tissue has great tensile strength that resists pulling forces especially well in one direction. DRCT has a very poor blood supply, which is why damaged tendons and ligaments are slow to heal.
Rubidium is the second most electropositive of the stable alkali metals and has a very low first ionization energy of only 403 kJ/mol. It has an electron configuration of [Kr]5s1 and is photosensitive. Due to its strong electropositive nature, rubidium reacts explosively with water to produce rubidium hydroxide and hydrogen gas. As with all the alkali metals, the reaction is usually vigorous enough to ignite metal or the hydrogen gas produced by the reaction, potentially causing an explosion. Rubidium, being denser than potassium, sinks in water, reacting violently; caesium explodes on contact with water. However, the reaction rates of all alkali metals depend upon surface area of metal in contact with water, with small metal droplets giving explosive rates. Rubidium has also been reported to ignite spontaneously in air.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.